Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens (EUCALYPTUS)
This is a conventional efficacy trial to validate the results from previous clinical trials for younger children; the 12-month efficacy results will be used to predict the 3-year treatment efficacy.
This is a randomized, controlled (1:1), multisite, subject- and observer-masked, 2-arm parallel group study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Vanessa Tasso, MA, MBA
- Phone Number: 949-751-7039
- Email: vtasso@sightglassvision.com
Study Contact Backup
- Name: Jennifer S Hill, BS
- Phone Number: 678-361-4877
- Email: jhill@sightglassvision.com
Study Locations
-
-
California
-
Oakland, California, United States, 94607
- Recruiting
- Elsa Pao, OD
-
Contact:
- Vanessa Chen
- Phone Number: 510-238-9797
-
Principal Investigator:
- Elsa Pao, OD
-
San Diego, California, United States, 92131
- Recruiting
- Scripps Poway Eyecare
-
Principal Investigator:
- Keith Wan, OD
-
Contact:
- Leslie Shan, OD
- Phone Number: 858-530-2800
-
San Francisco, California, United States, 94127
- Recruiting
- Pacific Rims Optometry
-
Contact:
- Aileen Guzman
- Phone Number: 415-655-3937
-
Principal Investigator:
- Selena Chan, OD
-
Santa Ana, California, United States, 92704
- Recruiting
- Paje Optometric
-
Contact:
- Daisy Magdaleno
- Phone Number: 714-557-9492
-
Principal Investigator:
- Vanessa Grichine, OD
-
-
Florida
-
Longwood, Florida, United States, 32779
- Recruiting
- Omega Vision Center
-
Contact:
- Renee Warren
- Phone Number: 407-869-4733
-
Principal Investigator:
- Christopher Pearson, OD
-
-
Georgia
-
Marietta, Georgia, United States, 30060
- Recruiting
- Marietta Eye Clinic
-
Contact:
- Doreatha Kennerly
- Phone Number: 2522 678-803-2600
-
Principal Investigator:
- Monica Bratton, MD
-
-
Illinois
-
Chicago, Illinois, United States, 60616
- Recruiting
- Ilinois College of Optometry
-
Contact:
- Jessica Martinez
- Phone Number: 312-949-7000
-
Principal Investigator:
- Yi Pang, OD
-
-
Kansas
-
Pittsburg, Kansas, United States, 66762
- Recruiting
- Kannarr Eye Care
-
Contact:
- Megan Compton, RN
- Phone Number: 620-235-1737
-
Principal Investigator:
- Shane Kannarr, OD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- New England College of Optometry
-
Principal Investigator:
- Katherine Green, OD
-
Contact:
- Lilly Cheam
- Phone Number: 617-266-2030
-
-
Missouri
-
Raytown, Missouri, United States, 64133
- Recruiting
- Advanced Eyecare PC
-
Principal Investigator:
- Richard Wilson, OD
-
Contact:
- Tamara Urias
- Phone Number: 816-353-1872
-
-
Ohio
-
Athens, Ohio, United States, 45701
- Recruiting
- Athens Eye Care
-
Contact:
- Shane Foster, OD
-
Principal Investigator:
- Shane Foster, OD
-
Contact:
- Jen Brite
- Phone Number: 740-594-2271
-
Granville, Ohio, United States, 43023
- Recruiting
- ProCare Vision Centers, Inc.
-
Contact:
- Katherine Bickle, OD
-
Principal Investigator:
- Katherine Bickle, OD
-
-
Texas
-
Beaumont, Texas, United States, 77706
- Recruiting
- Texas State Optical - Dowlen
-
Contact:
- Bobbie Hampton
- Phone Number: 409-899-9999
-
Principal Investigator:
- Samir Patel, OD
-
Bellaire, Texas, United States, 77401
- Recruiting
- Bellaire Family Eye Care
-
Contact:
- Ashley Tucker, OD
-
Principal Investigator:
- Ashley Tucker, OD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Children 6 - 8 years of age (inclusive) at time of informed consent/assent;
- Spherical equivalent refractive error between -0.75 and -4.50 D inclusive (by manifest refraction) in each eye;
- Astigmatism if present, less than or equal to -1.25 DC (by manifest refraction) in each eye;
- Best corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen equivalent) or better in each eye;
- The difference in spherical equivalent power between the two eyes (anisometropia based on manifest refraction) must be less than or equal to 1.50 D;
- Agree to wear the assigned spectacles constantly except for sleeping, swimming, or other activities in which spectacle wear would be dangerous or otherwise not possible (minimum of 10 hours per day);
- Ability to comply with study procedures, including high and low contrast visual acuity, axial length, and cycloplegic autorefraction measurements taken for both eyes at the baseline visit;
- Willingness to participate in the trial for 24 months without contact lens wear;
- The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed copy of the form.
Exclusion Criteria:
- Subject has previously or currently wears contact lenses (greater than 1-month usage);
- Current or prior use of bifocals, progressive addition spectacle lenses
- Current or prior use of any myopia control treatment (e.g., atropine, multifocal contact lenses, orthokeratology);
- Amblyopia in either eye;
- Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction;
- Any ocular or systemic conditions that could influence refractive development or status [e.g., keratoconus, congenital glaucoma, ocular trauma, diabetes, Marfan syndrome or other connective tissue disorder, Down's syndrome, family history of poor night vision (to prevent against enrolling subjects with congenital stationary night blindness)];
- Known allergy to proparacaine, tetracaine, or tropicamide;
- Participation in any investigational clinical study within 30 days of the Baseline visit;
- Subject's sibling or other household member is already enrolled in this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Test Arm 2
Single vision, impact-resistant spectacle lenses
|
Single vision, impact-resistant spectacle lenses
|
|
Experimental: Test Arm 1
Single vision, impact-resistant spectacle lenses
|
Use of single vision, impact-resistant spectacle lenses may reduce the rate of progression of juvenile myopia
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Spherical equivalent refraction
Time Frame: 12 months
|
Change in spherical equivalent refraction from baseline
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Axial length
Time Frame: 12 months
|
Change in axial length from baseline
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CPRO-2304-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.